Instil Bio Q4 net loss $1.82/sh; cash $115.1M; AXN-2510 NSCLC data expected 1H2025

Instil Bio, Inc.

GAAP net loss per share $1.82 in Q4, full year $11.39; non-GAAP $1.08 and $7.59 respectively.
Cash, equivalents, restricted cash and marketable securities $115.1M at Dec 31, 2024, down from $175.0M year-end 2023; runway beyond 2026.
Clinical data for AXN-2510 (PD-L1xVEGF bispecific) monotherapy in R/R NSCLC anticipated 1H2025; safety data across ~100 patients.
ImmuneOnco to initiate 1L NSCLC patient enrollment in China Phase 1b/2 trial of AXN-2510 plus chemo in Q2 2025; US trial expected before end of 2025.
R&D expenses $1.1M Q4 (vs $2.0M prior year); G&A $10.4M Q4; restructuring charges $0.3M Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.